PROK - ProKidney Corp. Stock Price, Fair Value and News

2.39USD0.00 (0.00%)Market Closed

Market Summary

USD2.390.00

Market Closed

0.00%

PROK Alerts

1 major insider sales recently.

PROK Stock Price

View Fullscreen

PROK RSI Chart

PROK Valuation

Market Cap

160.5M

Price/Earnings (Trailing)

-3.27

Price/Sales (Trailing)

7.27

EV/EBITDA

-0.79

Price/Free Cashflow

-1.29

PROK Price/Sales (Trailing)

PROK Profitability

EBT Margin

-586.20%

Return on Equity

4.45%

Return on Assets

-11.67%

Free Cashflow Yield

-77.45%

PROK Fundamentals

PROK Revenue

Revenue (TTM)

22.1M

Rev. Growth (Yr)

19.95%

Rev. Growth (Qtr)

-4.71%

PROK Earnings

Earnings (TTM)

-49.1M

Earnings Growth (Yr)

132.23%

Earnings Growth (Qtr)

172.11%

Breaking Down PROK Revenue

52 Week Range

2.42

(Low)(High)

Last 7 days

15.5%

Last 30 days

60.4%

Last 90 days

92.7%

How does PROK drawdown profile look like?

PROK Financial Health

Current Ratio

14.94

PROK Investor Care

Shares Dilution (1Y)

9.09%

Diluted EPS (TTM)

-0.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	11.6M	17.2M	21.2M	22.1M
2022	0	0	4.8M	6.0M
2021	0	1.2M	2.4M	3.6M
2020	0	0	0	43.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ProKidney Corp.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 22, 2024	weber darin j.	sold	-41,315	2.5134	-16,438	svp of regulatory development
Apr 18, 2024	weber darin j.	sold	-2,028	2.535	-800	svp of regulatory development
Apr 16, 2024	weber darin j.	sold	-43,095	2.5	-17,238	svp of regulatory development
Apr 12, 2024	weber darin j.	sold	-145,498	1.73	-84,103	svp of regulatory development
Apr 01, 2024	weber darin j.	sold	-507	1.69	-300	svp of regulatory development
Feb 05, 2024	girolamo todd c	acquired	-	-	81,928	chief legal officer
Feb 05, 2024	legorreta pablo g.	acquired	-	-	748,952	-
Feb 05, 2024	legorreta pablo g.	sold	-	-	-748,952	-
Feb 05, 2024	weber darin j.	acquired	-	-	137,073	svp of regulatory development
Nov 19, 2023	palihapitiya chamath	sold	-9,498,580	1.309	-7,256,370	-

Which funds bought or sold PROK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	SG Americas Securities, LLC	reduced	-71.15	-61,000	22,000	-%
May 03, 2024	Avion Wealth	new	-	1,000	1,000	-%
May 03, 2024	SIGNATUREFD, LLC	unchanged	-	-21.00	246	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	18.00	18.00	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-3.12	-24,451	203,311	-%
Apr 24, 2024	Zullo Investment Group, Inc.	new	-	31,849	31,849	0.01%
Apr 23, 2024	FIFTH THIRD BANCORP	sold off	-100	-93.00	-	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-66.67	-8,000	3,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	sold off	-100	-151,571	-	-%

Are Funds Buying or Selling PROK?

Are funds buying PROK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PROK

No. of Funds

PROK Alerts

1 major insider sales recently.

Unveiling ProKidney Corp.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	suvretta capital management, llc	5.8%	3,867,847	SC 13G/A
Feb 09, 2024	morgan stanley	16.1%	10,775,670	SC 13G/A
Feb 06, 2024	tolerantia, llc	37.6%	88,639,961	SC 13D/A
Nov 20, 2023	palihapitiya chamath	4.5%	3e+06	SC 13D/A
Nov 06, 2023	palihapitiya chamath	17.6%	11,795,700	SC 13D/A
Nov 02, 2023	tolerantia, llc	38.0%	89,388,913	SC 13D
Oct 27, 2023	palihapitiya chamath	20.4%	12,592,500	SC 13D/A
Oct 19, 2023	palihapitiya chamath	21.7%	13,361,473	SC 13D/A
Feb 10, 2023	morgan stanley	17.8%	10,934,182	SC 13G/A

Recent SEC filings of ProKidney Corp.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 23, 2024	4	Insider Trading
Apr 18, 2024	144	Notice of Insider Sale Intent
Apr 17, 2024	4	Insider Trading
Apr 16, 2024	144	Notice of Insider Sale Intent
Apr 16, 2024	4	Insider Trading
Apr 12, 2024	144	Notice of Insider Sale Intent
Apr 02, 2024	3	Insider Trading
Apr 02, 2024	4	Insider Trading

ProKidney Corp. News

Latest updates

ProKidney Corp. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4	2021Q3	2021Q2	2020Q4
Revenue	-4.7%	5,280,000	5,541,000	5,965,000	5,297,000	4,402,000	1,581,000	1,054,667	528,333	2,000	-
Operating Expenses	-48.1%	24,210,000	46,617,000	39,819,000	40,876,000	30,235,000	35,572,000	13,709,000	17,081,000	12,717,000	-
S&GA Expenses	-88.3%	1,682,000	14,419,000	13,455,000	15,259,000	9,345,000	14,440,000	3,024,000	2,339,000	1,748,000	-
R&D Expenses	-30.0%	22,528,000	32,198,000	26,364,000	25,617,000	20,890,000	21,132,000	10,685,000	14,742,000	10,969,000	-
EBITDA Margin	9.2%	-5.69	-6.26	-7.31	-9.73	-24.07	-27.54	-14.73	-10.76	-21.13	-605
Interest Expenses	50.0%	3,000	2,000	4,000	3,000	-428,000	29,000	-500	1,000	-	-
Income Taxes	205.7%	2,791,000	913,000	965,000	1,327,000	-1,262,000	-75,000	98,000	-60,000	10,000	-
Earnings Before Taxes	53.9%	-18,933,000	-41,078,000	-33,858,000	-35,582,000	-25,835,000	-34,020,000	-13,708,000	-17,082,000	-12,715,000	-
EBT Margin	8.8%	-5.86	-6.43	-7.50	-10.02	-24.61	-28.18	-15.28	-11.15	-21.92	-627
Net Income	172.1%	7,921,000	-10,984,000	-9,118,000	-36,909,000	-24,573,000	-33,945,000	-13,670,000	-17,142,000	-12,725,000	-
Net Income Margin	42.2%	-2.22	-3.85	-6.06	-10.12	-24.76	-28.62	-15.29	-11.06	-21.73	-622
Free Cashflow	47.9%	-26,956,000	-51,716,000	-18,616,000	-26,978,000	-16,067,000	-23,158,000	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-6.9%	421	452	484	495	518	532	54.00	54.00	40.00	251	134	17.00
Current Assets	-7.9%	374	406	466	480	505	519	34.00	35.00	27.00	1.00	0.00	6.00
Cash Equivalents	-68.3%	61.00	191	244	272	490	506	22.00	30.00	21.00	4.00	12.00	5.00
Net PPE	-1.1%	42.00	43.00	15.00	12.00	11.00	11.00	11.00	11.00	11.00	-	-	9.00
Liabilities	23.7%	29.00	24.00	27.00	14.00	13.00	12.00	16.00	13.00	13.00	8.00	-	-
Current Liabilities	19.3%	25.00	21.00	24.00	11.00	11.00	10.00	46.00	32.00	12.00	0.00	1.00	6.00
Shareholder's Equity	-Infinity%	-1,103	-	-	-	-1,096	-	7.00	20.00	27.00	10.00	16.00	10.00
Retained Earnings	-0.5%	-1,139	-1,133	-1,353	-1,623	-1,104	-1,097	-251	-229	-161	-6.32	-6.06	-106
Additional Paid-In Capital	-12.7%	36.00	41.00	31.00	22.00	7.00	1.00	-	-	-	-	0.00	-
Shares Outstanding	-100.0%	-	174	174	173	172	171	187	187	187	157	145	115
Float	-	-	-	689	-	-	-	248,750	-	-	-	251	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)													(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Cashflow From Operations	-6.8%	-25,384	-23,777	-14,916	-25,992	-15,761	-22,843	-23,026	-15,459	-12,990	-18,214	-19.84	-7,256	-
Share Based Compensation	-149.0%	-6,370	12,994	11,202	13,020	8,940	4,844	8,001	52,684	175	174	175	175	-
Cashflow From Investing	-237.8%	-95,844	-28,374	-13,153	-192,612	-306	-207	-386	-839	-	-1,259	-2,004	-1,389	-
Cashflow From Financing	-73069.2%	-9,512	-13.00	-13.00	-13.00	-8.00	507,495	15,492	25,542	-28.18	21,242	243	19,993	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PROK Income Statement

2023-12-31

Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Operating expenses

Research and development

$ 106,707

$ 82,070

$ 46,255

General and administrative

44,815

70,937

8,855

Total operating expenses

151,522

153,007

55,110

Operating loss

(151,522)

(153,007)

(55,110)

Interest income

22,083

5,983

Interest expense

(12)

215

Net loss before income taxes

(129,451)

(147,239)

(55,108)

Income tax expense (benefit)

5,996

896

Net and comprehensive loss before noncontrolling interest

(135,447)

(148,135)

(55,146)

Net loss and comprehensive loss attributable to noncontrolling interest

(99,979)

(40,103)

Net loss available to Class A ordinary shareholders

(35,468)

(55,146)

Common Class A [Member]

Operating expenses

Net loss available to Class A ordinary shareholders

$ (35,468)

$ (108,032)

$ (55,146)

Weighted average Class A ordinary shares or ProKidney Corp. outstanding, Basic

^[1]

61,714,225

61,540,231

Weighted average Class A ordinary shares or ProKidney Corp. outstanding, Diluted

^[1]

61,714,225

61,540,231

Net loss per ordinary share , Basic

^[1]

$ (0.57)

$ (0.23)

Net loss per ordinary share , Diluted

^[1]

$ (0.57)

$ (0.23)

[1]

For the year ended December 31, 2022, net loss per Class A ordinary share and weighted average Class A ordinary shares outstanding reflects the period from July 11, 2022 through December 31, 2022, the period following the Business Combination, as defined in Note 1. For more information refer to Note 9.

PROK Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 60,649,000	$ 490,252,000
Marketable securities	302,301,000	0
Interest receivable	1,375,000	0
Prepaid assets	3,399,000	2,624,000
Prepaid clinical	6,413,000	10,459,000
Other current assets	9,000	1,384,000
Total Current Assets	374,146,000	504,719,000
Fixed assets, net	42,143,000	10,708,000
Right of use assets, net	4,263,000	2,356,000
Intangible assets, net	0	213,000
Total assets	420,552,000	517,996,000
Current liabilities
Accounts payable	5,098,000	3,044,000
Lease liabilities	803,000	493,000
Accrued expenses and other	17,665,000	7,336,000
Income taxes payable	1,472,000	0
Total current liabilities	25,038,000	10,873,000
Income tax payable, net of current portion	568,000	278,000
Lease liabilities, net of current portion	3,610,000	1,906,000
Total liabilities	29,216,000	13,057,000
Commitments and Contingencies
Redeemable noncontrolling interest	1,494,732,000	1,601,555,000
Shareholders' deficit / members' equity:
Additional paid-in capital	36,114,000	7,476,000
Accumulated other comprehensive loss	130,000	0
Accumulated deficit	(1,139,663,000)	(1,104,116,000)
Total shareholders' deficit / members equity	(1,103,396,000)	(1,096,616,000)
Total liabilities and shareholders' deficit/members' equity	420,552,000	517,996,000
Common Class A [Member]
Shareholders' deficit / members' equity:
Common stock value	6,000	6,000
Common Class B [Member]
Shareholders' deficit / members' equity:
Common stock value	$ 17,000	$ 18,000

About ProKidney Corp.

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture that is in Phase I for REACT in patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

CEO	Dr. Timothy A. Bertram D.V.M., Ph.D.
WEBSITE	prokidney.com
INDUSTRY	Biotechnology
EMPLOYEES	87

ProKidney Corp. Frequently Asked Questions

What is the ticker symbol for ProKidney Corp.? What does PROK stand for in stocks?

PROK is the stock ticker symbol of ProKidney Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ProKidney Corp. (PROK)?

As of Tue May 07 2024, market cap of ProKidney Corp. is 160.46 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PROK stock?

You can check PROK's fair value in chart for subscribers.

What is the fair value of PROK stock?

You can check PROK's fair value in chart for subscribers. The fair value of ProKidney Corp. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ProKidney Corp. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PROK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ProKidney Corp. a good stock to buy?

The fair value guage provides a quick view whether PROK is over valued or under valued. Whether ProKidney Corp. is cheap or expensive depends on the assumptions which impact ProKidney Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PROK.

What is ProKidney Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, PROK's PE ratio (Price to Earnings) is -3.27 and Price to Sales (PS) ratio is 7.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PROK PE ratio will change depending on the future growth rate expectations of investors.